XC221 200 mg: Clinical Trials

3 trials of XC221 200 mg, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

3 completed. 2 Phase 2, 1 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 22Completed 2
Phase 11Completed 1

Follow XC221 200 mg: new trials by email Literature Review of XC221 200 mg trials Research Report on XC221 200 mg

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study to Evaluate the Safety, Tolerability and Efficacy of XC221 in Patients With Uncomplicated Influenza or Other Acute Viral Upper Respiratory Infections
XC221 100 mg, XC221 200 mg, Placebo - Influenza, Viral Respiratory Infection
Phase 2CompletedValenta Pharm JSC2552021-10-012023-07-27
Study to Assess Efficacy and Safety of XC221 in the Treatment of Influenza and Other Acute Respiratory Viral Infections
XC221 100 mg, XC221 200 mg, Placebo - Acute Respiratory Viral Infections, Influenza
Phase 2CompletedPHARMENTERPRISES LLC1202018-02-122019-11-04
Study to Assess Safety, Tolerability and Pharmacokinetics of XC221 in Healthy Volunteers
XC221 60 mg, XC221 200 mg, Placebo - Influenza, Acute Respiratory Infection
Phase 1CompletedPHARMENTERPRISES LLC322017-05-222018-03-08

Conditions studied

Influenza, Human (3)

Sponsors

PHARMENTERPRISES LLC (2)  ·  Valenta Pharm JSC (1)

Countries

Russia (3)